SEC For		۰ I		OTA	тее					EVOUA								
FORM 4 UNITED STAT				IES	ES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See					d purs	NT OF CHANGES IN BENEFICIAL OWNERSHIP pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										OMB Number: 3235-028 Estimated average burden hours per response: 0.		
1. Name and Address of Reporting Person <sup>*</sup> Hawkins Richard J						PLUS THERAPEUTICS, INC. [ PSTV ] (Chec								Relationship of Reporting Person(s) to Issuer neck all applicable) X Director 10% Owner				
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)     Officer (g 02/22/2024							(give title	(give title Other (specify below)					
C/O PLUS THERAPEUTICS INC. 4200 MARATHON BOULEVARD, SUITE 200				4. 1	Line) X								ual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting					
(Street) AUSTIN	T	X	78756			1 مار	1065	1(c	) Transa	ction In	dication		Perso					
(City)	(S	ate)	(Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													
		Tab	le I - Non	-Deriv	ative	e Sec	curitie	s Ac	cquired, D	isposed	of, or Be	eneficia	lly Owned	k				
1. Title of Security (Instr. 3) 2. Transa Date (Month/Date)					Execution D		n Date	Code (Ins				Benefici Owned	es ally Following	Form: (D) or	orm: Direct D) or Indirect ) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code V	Amount	(A) c (D)	Price	rice Reported Transaction (Instr. 3 and					
		T							luired, Dis s, options				y Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution I if any (Month/Day	Date,	4. Transactio Code (Inst 8)				6. Date Exer Expiration D (Month/Day/	ate	and 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$2.03	02/22/2024			Α		2,250		(1)	02/22/2034	Common Stock	2,250	\$0.00	2,250		D		

Explanation of Responses:

1. The options vest monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the options vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.

<u>/s/ Andrew Sims, attorn</u> fact	<u>ey-in-</u>	<u>02/26/2024</u>		
** Signature of Reporting Pe	erson E	Date		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.